- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BioAdaptives Inc.: BioAdaptives Announces National Launch of Pawpa Regen | 3 | GlobeNewswire (USA) | ||
| 28.05. | BioAdaptives Inc.: BioAdaptives PawPa Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR Scale Improvements | 1 | GlobeNewswire (USA) | ||
| 13.05. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.04. | BIOADAPTIVES, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | BIOADAPTIVES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 13.03. | BioAdaptives Inc.: Zeranovia Weight Loss Product Shows Promising Results in Dosage Trial | 111 | GlobeNewswire (Europe) | LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia.... ► Artikel lesen | |
| BIOADAPTIVES Aktie jetzt für 0€ handeln | |||||
| 07.02. | BIOADAPTIVES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.02. | BioAdaptives Inc.: BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors | 2 | GlobeNewswire (USA) | ||
| 03.02. | BioAdaptives Inc.: BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 21.01. | BioAdaptives Inc.: BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders | 1 | GlobeNewswire (USA) | ||
| 25.11.24 | BioAdaptives Inc.: BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia | 126 | GlobeNewswire (Europe) | LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN - BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia. The trial, approved... ► Artikel lesen | |
| 13.11.24 | BioAdaptives Inc.: BioAdaptives, Inc. Announces Complete Product Overhaul with New Line of Scientifically Advanced Solutions | 106 | GlobeNewswire (Europe) | LAS VEGAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a leading provider of innovative nutritional products, announces today a transformative shift in its product... ► Artikel lesen | |
| 29.10.24 | BioAdaptives Inc.: BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split | 86 | GlobeNewswire (Europe) | LAS VEGAS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- via IBN -- Due to a website maintenance error, a draft of a letter to BioAdaptives® (OTC: BDPT) shareholders was made available on the BioAdaptives® website.... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | 0,00 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | 0,00 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | 0,00 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | 0,00 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | 0,00 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| QIAGEN | 41,170 | +0,41 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | ||
| NUVALENT | 79,66 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| EVOTEC | 7,242 | +1,46 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen |
BIOADAPTIVES INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOADAPTIVES INC finden Sie auf Wallstreet Online.